Cancer Family
Malignant Eye Neoplasm
CI-CAN-00000231Explore in graph →
83 active trials2 approved drugs19 evidence items
- NCIt
- C4767
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000231Explore in graph →
Clinical trials
446 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (67)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04344652 | Photoscreening for Retinoblastoma | withdrawn | N/A | 0 | Phoenix Children's HospitalOTHER | 0 | Sep 26, 2025 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05677373 |
| Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Alliance for Clinical Trials in OncologyOTHER |
| 0 |
| Aug 18, 2023 |
| clinicaltrials |
| NCT01930968 | Definity for Ultrasound of Intraocular Tumors | withdrawn | — | 0 | Emory UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | withdrawn | Early Phase 1 | 0 | University of MiamiOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT00980551 | Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma(RELRB1) | withdrawn | N/A | 0 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02655432 | Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population(POPH) | withdrawn | — | 0 | Université de MontréalOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 3 | Dec 3, 2015 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT00621439 | Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye | withdrawn | N/A | 0 | Emory UniversityOTHER | 0 | Dec 2, 2013 | clinicaltrials |
| NCT01151748 | Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | May 14, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Sep 26, 2025source: clinicaltrials